AI Tokens
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Analysis of Investments

Microsoft Excel

Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities

Allergan Inc., adjustment to net earnings attributable to Allergan, Inc.

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Net earnings attributable to Allergan, Inc. (as reported) 1,524,200 985,100 1,098,800 934,500 600
Add: Unrealized holding gain on available-for-sale securities, net of tax 5,800 — — — —
Net earnings attributable to Allergan, Inc. (adjusted) 1,530,000 985,100 1,098,800 934,500 600

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).


Net earnings attributable to Allergan, Inc. exhibited significant growth over the five-year period ending December 31, 2014. Following a nominal baseline in 2010, earnings rose sharply through 2012, experienced a moderate contraction in 2013, and reached a peak in 2014.

Earnings Trajectory and Volatility
Reported net earnings grew from 600 thousand US dollars in 2010 to 1.524 billion US dollars in 2014. A substantial increase occurred between 2010 and 2011, with earnings continuing to climb to 1.098 billion US dollars in 2012. A slight decline to 985.1 million US dollars was observed in 2013, followed by a recovery and significant expansion to 1.524 billion US dollars in 2014.
Convergence and Divergence of Reported and Adjusted Earnings
From 2010 through 2013, reported net earnings and adjusted net earnings were identical, indicating an absence of material adjustments during those four fiscal years. A divergence occurred only in 2014, where adjusted net earnings of 1.530 billion US dollars exceeded reported net earnings of 1.524 billion US dollars.
Impact of Mark-to-Market Adjustments
The variance of 5.8 million US dollars identified in 2014 is attributable to the mark-to-market adjustment of available-for-sale securities. Since the adjusted net earnings are higher than the reported net earnings, the data indicates that a non-cash unrealized loss was recorded in the reported figures, which was then excluded in the adjusted calculation to neutralize the impact of market fluctuations on the company's core financial performance.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)

Allergan Inc., Profitability Ratios: Reported vs. Adjusted

Allergan Inc., adjusted profitability ratios

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Net Profit Margin
Reported net profit margin 21.39% 15.90% 19.25% 17.48% 0.01%
Adjusted net profit margin 21.47% 15.90% 19.25% 17.48% 0.01%
Return on Equity (ROE)
Reported ROE 19.66% 15.24% 18.82% 17.60% 0.01%
Adjusted ROE 19.73% 15.24% 18.82% 17.60% 0.01%
Return on Assets (ROA)
Reported ROA 12.28% 9.32% 11.97% 10.98% 0.01%
Adjusted ROA 12.32% 9.32% 11.97% 10.98% 0.01%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).


The financial performance between December 31, 2010, and December 31, 2014, is characterized by a significant recovery and subsequent growth in profitability and capital efficiency. After a near-zero baseline in 2010, all primary profitability metrics experienced a sharp increase in 2011, followed by a period of fluctuation that ultimately peaked in 2014.

Net Profit Margin
A substantial expansion is observed, with the reported net profit margin rising from 0.01% in 2010 to a peak of 21.39% in 2014. A temporary contraction occurred in 2013, where the margin declined to 15.90% from 19.25% in 2012, before rebounding strongly in the final year of the period.
Return on Equity (ROE)
ROE follows a trajectory nearly identical to the net profit margin. The metric surged from 0.01% in 2010 to 17.60% in 2011, reaching its highest reported level of 19.66% in 2014. The dip observed in 2013 to 15.24% indicates a momentary decline in the efficiency of generating profits from shareholders' equity.
Return on Assets (ROA)
ROA demonstrates consistent alignment with the other profitability indicators. After the initial jump to 10.98% in 2011, the ratio reached 11.97% in 2012, declined to 9.32% in 2013, and recovered to a period high of 12.28% by 2014. This suggests a stable relationship between net income and the total asset base.
Comparison of Reported and Adjusted Metrics
Between 2010 and 2013, reported and adjusted figures for profit margin, ROE, and ROA are identical, indicating an absence of significant non-recurring items impacting these ratios. However, a divergence emerges in 2014, where adjusted figures are consistently higher than reported figures. Specifically, the adjusted net profit margin reached 21.47% compared to the reported 21.39%, and adjusted ROE reached 19.73% compared to the reported 19.66%, suggesting that specific adjustments—potentially related to the mark-to-market valuation of available-for-sale securities—positively impacted the adjusted results.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Product net sales 7,126,100 6,197,500 5,708,800 5,347,100 4,819,600
Profitability Ratio
Net profit margin1 21.39% 15.90% 19.25% 17.48% 0.01%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net earnings attributable to Allergan, Inc. 1,530,000 985,100 1,098,800 934,500 600
Product net sales 7,126,100 6,197,500 5,708,800 5,347,100 4,819,600
Profitability Ratio
Adjusted net profit margin2 21.47% 15.90% 19.25% 17.48% 0.01%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

2014 Calculations

1 Net profit margin = 100 × Net earnings attributable to Allergan, Inc. ÷ Product net sales
= 100 × 1,524,200 ÷ 7,126,100 = 21.39%

2 Adjusted net profit margin = 100 × Adjusted net earnings attributable to Allergan, Inc. ÷ Product net sales
= 100 × 1,530,000 ÷ 7,126,100 = 21.47%


Profitability exhibited significant growth and expansion between 2010 and 2014, transitioning from a near-break-even state to high-margin performance. The overall trajectory indicates a substantial increase in earning capacity and operational efficiency following the 2010 period.

Adjusted Net Profit Margin Trend
The adjusted net profit margin rose sharply from 0.01% in 2010 to 17.48% in 2011, subsequently reaching 19.25% in 2012. A moderate decline to 15.90% was recorded in 2013, followed by a peak of 21.47% in 2014, representing the highest level of profitability within the analyzed timeframe.
Adjusted Net Earnings Progression
Net earnings attributable to the company experienced substantial growth, increasing from US$ 600 thousand in 2010 to US$ 1.53 billion in 2014. While a slight contraction occurred in 2013, with earnings falling to US$ 985.1 million from the US$ 1.099 billion reported in 2012, the 2014 results demonstrate a strong recovery and significant absolute growth.
Analysis of Reporting Divergence
Reported and adjusted financial metrics were identical from 2010 through 2013. A divergence occurred in 2014, where adjusted net earnings were US$ 5.8 million higher than reported earnings. This adjustment resulted in an adjusted net profit margin of 21.47%, which is 8 basis points higher than the reported margin of 21.39%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Total Allergan, Inc. stockholders’ equity 7,753,000 6,463,200 5,837,100 5,309,600 4,757,700
Profitability Ratio
ROE1 19.66% 15.24% 18.82% 17.60% 0.01%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net earnings attributable to Allergan, Inc. 1,530,000 985,100 1,098,800 934,500 600
Total Allergan, Inc. stockholders’ equity 7,753,000 6,463,200 5,837,100 5,309,600 4,757,700
Profitability Ratio
Adjusted ROE2 19.73% 15.24% 18.82% 17.60% 0.01%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

2014 Calculations

1 ROE = 100 × Net earnings attributable to Allergan, Inc. ÷ Total Allergan, Inc. stockholders’ equity
= 100 × 1,524,200 ÷ 7,753,000 = 19.66%

2 Adjusted ROE = 100 × Adjusted net earnings attributable to Allergan, Inc. ÷ Total Allergan, Inc. stockholders’ equity
= 100 × 1,530,000 ÷ 7,753,000 = 19.73%


A significant upward trajectory in profitability and investment efficiency is observed between 2010 and 2014. After an initial period of negligible earnings and returns in 2010, the company experienced a substantial surge in performance, maintaining a generally positive growth trend despite a moderate decline in 2013.

Net Earnings Trends
Adjusted net earnings grew from 600 thousand US dollars in 2010 to 1.53 billion US dollars by 2014. A period of steady growth occurred between 2011 and 2012, followed by a temporary contraction in 2013 where earnings fell to 985.1 million US dollars. A strong recovery followed in 2014, marking the peak earnings period within the analyzed timeframe.
Adjusted Return on Equity (ROE)
The adjusted ROE demonstrates a parallel trend to net earnings, rising sharply from 0.01% in 2010 to 17.60% in 2011. The ratio peaked at 19.73% in 2014. The decline to 15.24% in 2013 indicates a temporary reduction in the efficiency of generating profits from shareholders' equity, which was subsequently reversed in the following year.
Comparison of Reported and Adjusted Metrics
For the majority of the period from 2010 to 2013, reported and adjusted figures remained identical. A divergence emerged in 2014, where adjusted net earnings were slightly higher than reported earnings, resulting in an adjusted ROE of 19.73% compared to a reported ROE of 19.66%. This suggests the impact of specific non-recurring items in the final year of the sequence.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Total assets 12,415,700 10,574,300 9,179,300 8,508,600 8,308,100
Profitability Ratio
ROA1 12.28% 9.32% 11.97% 10.98% 0.01%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net earnings attributable to Allergan, Inc. 1,530,000 985,100 1,098,800 934,500 600
Total assets 12,415,700 10,574,300 9,179,300 8,508,600 8,308,100
Profitability Ratio
Adjusted ROA2 12.32% 9.32% 11.97% 10.98% 0.01%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

2014 Calculations

1 ROA = 100 × Net earnings attributable to Allergan, Inc. ÷ Total assets
= 100 × 1,524,200 ÷ 12,415,700 = 12.28%

2 Adjusted ROA = 100 × Adjusted net earnings attributable to Allergan, Inc. ÷ Total assets
= 100 × 1,530,000 ÷ 12,415,700 = 12.32%


The financial performance between 2010 and 2014 is characterized by a substantial trajectory of growth in both overall profitability and asset utilization efficiency.

Earnings Trends
Net earnings experienced a dramatic escalation, rising from a nominal 600 thousand US dollars in 2010 to 1.53 billion US dollars by 2014 on an adjusted basis. Growth remained strong through 2012, followed by a moderate contraction in 2013, and concluded with a significant surge in 2014.
Adjusted Return on Assets (ROA)
The Adjusted ROA closely mirrored the net earnings pattern, shifting from a negligible 0.01% in 2010 to a peak of 12.32% in 2014. The most significant expansion occurred between 2010 and 2011, where the ratio increased to 10.98%. A temporary dip to 9.32% was recorded in 2013, indicating a transient decline in the efficiency of asset deployment before returning to an upward trend in 2014.
Comparative Analysis of Reported and Adjusted Metrics
A high level of convergence is observed between reported and adjusted figures throughout the five-year period. For the majority of the timeline, the figures were identical, suggesting a minimal impact from non-recurring items. A slight divergence emerged in 2014, where adjusted net earnings were marginally higher than reported earnings, resulting in a corresponding increase in Adjusted ROA to 12.32% compared to the reported 12.28%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?